Q3 EPS Forecast for ANI Pharmaceuticals Lifted by Analyst

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) – HC Wainwright lifted their Q3 2025 earnings per share (EPS) estimates for shares of ANI Pharmaceuticals in a research note issued to investors on Wednesday, September 17th. HC Wainwright analyst B. Folkes now forecasts that the specialty pharmaceutical company will post earnings per share of $1.21 for the quarter, up from their previous forecast of $1.19. HC Wainwright currently has a “Buy” rating and a $121.00 target price on the stock. The consensus estimate for ANI Pharmaceuticals’ current full-year earnings is $3.86 per share. HC Wainwright also issued estimates for ANI Pharmaceuticals’ Q4 2025 earnings at $1.70 EPS, FY2025 earnings at $5.73 EPS and FY2026 earnings at $6.53 EPS.

ANIP has been the subject of a number of other research reports. Truist Financial increased their target price on shares of ANI Pharmaceuticals from $65.00 to $77.00 and gave the stock a “hold” rating in a research report on Monday, August 11th. Guggenheim boosted their target price on ANI Pharmaceuticals from $86.00 to $114.00 and gave the company a “buy” rating in a research note on Monday, September 8th. Piper Sandler reaffirmed an “overweight” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Friday, August 8th. Zacks Research raised shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 21st. Finally, Wall Street Zen upgraded shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 16th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $93.00.

ANI Pharmaceuticals Price Performance

ANIP opened at $97.48 on Thursday. The firm has a market capitalization of $2.12 billion, a P/E ratio of -126.60 and a beta of 0.63. ANI Pharmaceuticals has a 12-month low of $52.50 and a 12-month high of $99.50. The company has a quick ratio of 1.96, a current ratio of 2.54 and a debt-to-equity ratio of 1.39. The stock has a fifty day moving average of $82.07 and a 200-day moving average of $70.72.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.42 by $0.38. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%.The company had revenue of $211.37 million for the quarter, compared to analyst estimates of $187.18 million. During the same period in the previous year, the firm earned $1.02 earnings per share. ANI Pharmaceuticals’s revenue for the quarter was up 53.2% compared to the same quarter last year.

Insiders Place Their Bets

In other news, Director Jeanne Thoma sold 21,540 shares of the firm’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $89.15, for a total value of $1,920,291.00. Following the sale, the director directly owned 23,405 shares of the company’s stock, valued at approximately $2,086,555.75. This trade represents a 47.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Nikhil Lalwani sold 56,960 shares of the business’s stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $85.93, for a total value of $4,894,572.80. Following the transaction, the chief executive officer directly owned 411,219 shares of the company’s stock, valued at $35,336,048.67. This represents a 12.17% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 412,830 shares of company stock worth $36,397,254 in the last ninety days. 11.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ANIP. Principal Financial Group Inc. boosted its position in shares of ANI Pharmaceuticals by 68.3% in the first quarter. Principal Financial Group Inc. now owns 157,798 shares of the specialty pharmaceutical company’s stock valued at $10,565,000 after acquiring an additional 64,021 shares during the period. Allspring Global Investments Holdings LLC increased its holdings in shares of ANI Pharmaceuticals by 53.3% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 8,949 shares of the specialty pharmaceutical company’s stock worth $599,000 after purchasing an additional 3,112 shares during the period. Invesco Ltd. raised its position in shares of ANI Pharmaceuticals by 1.0% during the first quarter. Invesco Ltd. now owns 199,567 shares of the specialty pharmaceutical company’s stock valued at $13,361,000 after buying an additional 2,022 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of ANI Pharmaceuticals by 163.8% in the first quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company’s stock valued at $95,000 after buying an additional 881 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in ANI Pharmaceuticals by 0.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 238,377 shares of the specialty pharmaceutical company’s stock worth $15,959,000 after buying an additional 2,220 shares in the last quarter. 76.05% of the stock is owned by institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.